ALKBH5 Gene Polymorphisms and Hepatoblastoma Susceptibility in Chinese Children
Table 1
Association between ALKBH5 gene polymorphisms and hepatoblastoma risk.
Genotype
Cases (N = 324)
Controls (N = 1476)
Crude OR (95% CI)
Adjusted OR (95% CI)b
rs1378602G>A (HWE = 0.373)
GG
277 (85.49)
1210 (81.98)
1.00
1.00
GA
43 (13.27)
256 (17.34)
0.73 (0.52–1.04)
0.082
0.73 (0.52–1.03)
0.076
AA
4 (1.23)
10 (0.68)
1.75 (0.54–5.61)
0.349
1.76 (0.55–5.67)
0.341
Additive
0.234
0.83 (0.61–1.13)
0.235
0.82 (0.60–1.13)
0.225
Dominant
47 (14.51)
266 (18.02)
0.131
0.77 (0.55–1.08)
0.132
0.77 (0.55–1.08)
0.124
Recessive
320 (98.77)
1466 (99.32)
0.301
1.83 (0.57–5.88)
0.309
1.85 (0.58–5.95)
0.301
rs8400G>A (HWE = 0.063)
GG
93 (28.70)
464 (31.44)
1.00
1.00
GA
164 (50.62)
758 (51.36)
1.08 (0.82–1.43)
0.592
1.08 (0.82–1.43)
0.600
AA
67 (20.68)
254 (17.21)
1.32 (0.93–1.87)
0.123
1.31 (0.92–1.86)
0.125
Additive
0.141
1.14 (0.96–1.36)
0.141
1.14 (0.96–1.36)
0.143
Dominant
231 (71.30)
1012 (68.56)
0.335
1.14 (0.87–1.48)
0.336
1.14 (0.87–1.48)
0.342
Recessive
257 (79.32)
1222 (82.79)
0.140
1.25 (0.93–1.70)
0.140
1.25 (0.93–1.69)
0.141
Combined effect of risk genotypesc
0
93 (28.70)
464 (31.44)
1.00
1.00
1
227 (70.06)
1002 (67.89)
1.13 (0.87–1.47)
0.365
1.13 (0.87–1.47)
0.372
2
4 (1.23)
10 (0.68)
0.260
2.00 (0.61–6.50)
0.251
2.01 (0.62–6.57)
0.246
0
93 (28.70)
464 (31.44)
1.00
1.00
1-2
231 (71.30)
1012 (68.56)
0.335
1.14 (0.87–1.48)
0.336
1.14 (0.87–1.48)
0.342
OR, odds ratio; CI, confidence interval; HWE, Hardy–Weinberg equilibrium. aχ2 test for genotype distributions between hepatoblastoma patients and cancer-free controls. bAdjusted for age and sex. cRisk genotypes were carriers with rs1378602 AA and rs8400GA/GG genotypes.
